Adjuvanted nanocarrier-based vaccines hold substantial potential for applications in novel
early-life immunization strategies. Here, via mouse and human age-specific in vitro …

Background Newborns display distinct immune responses, leaving them vulnerable to
infections and impairing immunization. Targeting newborn dendritic cells (DCs), which …

The highly conserved matrix protein 2 ectodomain (M2e) of influenza viruses presents a
compelling vaccine antigen candidate for stemming the pandemic threat of the mutation …

Nanoparticles (NPs)-based adjuvants are attracting much attention in the development of
vaccines. Previously, we reported a type of guanidyl-decorated polymeric NPs used as …

Immune checkpoint blockade (ICB) has revolutionized cancer treatment and led to complete
and durable responses, but only for a minority of patients. Resistance to ICB can largely be …

Immunization is key to preventing infectious diseases, a leading cause of death early in life.
However, due to age-specific immunity, vaccines often demonstrate reduced efficacy in …

Adjuvants are vaccine components that can boost the type, magnitude, breadth, and
durability of an immune response. We have previously demonstrated that certain adjuvant …

As the focus has shifted from traditional killed or live, attenuated vaccines toward subunit
vaccines, improvements in vaccine safety have been confronted with low immunogenicity of …

The activation of multiple Pattern Recognition Receptors (PRRs) has been demonstrated to
trigger inflammatory responses and coordinate the host's adaptive immunity during …

The SARS-CoV-2 virus has caused an unprecedented global crisis, and curtailing its spread
requires an effective vaccine which elicits a diverse and robust immune response. We have …